| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is making significant strides in product and service development, particularly with advancements in obesity treatment options and innovative healthcare delivery models. The success of the eczema drug EBGLYSS, along with positive clinical data from various initiatives, showcases the company's commitment to improving patient outcomes. However, the overall impact of clinical data progress remains moderate, suggesting that while advancements are promising, challenges in drug development continue to exist. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -2.7 is extremely bearish. The market sentiment at -0.3 is modestly bearish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. LLY is likely to move down since both trend sentiment and market sentiment are negative. The positive sentiment force for sector is at 0.6, and the negative at -0.9 on 2026-03-17. The forces of Stock Price Trend (-2.7), Valuation Sentiment (-1.7), Sector Price Trend (-1.4), and Sentiment towards Fundamentals (-0.4) will drive down the price. The forces of Option Sentiment (0.8), Price Level Sentiment (1), and Market Risk Appetite (2) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | 1%(0.1%) | 930.51 | 3.02% | -18 | -5.89% | -0.77% | -2.7 | -1.5 | 2.5% | -0.3 | Short | 60% | -0.4 | -5.6 |
| 2026-03-16 | 0%(0%) | 988.79 | 2.28% | 23 | 0.34% | -0.28% | -1 | 0.2 | 0.6% | 0.3 | Wait | 50% | 2.2 | -5 |
| 2026-03-15 | 0%(0%) | -1.1 | 0.2 | 0.5 | 1.7 | -1 | ||||||||
| 2026-03-14 | 0%(0%) | -1.1 | 0.2 | 0.4 | 1.5 | -1 | ||||||||
| 2026-03-13 | 0%(0%) | 985.42 | 2.29% | 17 | 0.9% | -0.67% | -1.1 | -0 | 0.8% | 0.7 | Short | 55% | 1.9 | 7 |
| 2026-03-12 | 0%(0%) | 976.64 | 2.26% | 3 | -2.3% | -0.45% | -0.8 | -0.4 | 1.1% | 0.5 | Wait | 50% | 1.3 | -4 |
| 2026-03-11 | 0%(0%) | 999.61 | 1.99% | 25 | -0.17% | -0.3% | -0.5 | 0.1 | 0.4% | 0.3 | Wait | 50% | 2.5 | 6.5 |
| 2026-03-10 | 0%(0%) | 1001.3 | 1.94% | 24 | -0.68% | -0.41% | -0.7 | 0.2 | 0.9% | 0.5 | Wait | 50% | 1.5 | -1 |
| 2026-03-09 | 0%(0%) | 1008.15 | 1.93% | 31 | 1.84% | -0.49% | -0.9 | 0.6 | 1.1% | 0.2 | Wait | 50% | 1.5 | -1 |
| 2026-03-08 | 0%(0%) | -1.6 | 0.6 | -0.3 | 2 | -1 | ||||||||
| Short is the preferred trading strategy with 60% chance of being right. Both trend sentiment and hourly trend are weak. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-03-17 22:48:11 The potential job losses due to AI are contributing to concerns about the sales of weight-loss drugs like Zepbound, reflecting a broader concern about the economy. |
| 2026-03-17 22:48:11 Analysts are questioning the hype around GLP-1 pills, indicating skepticism about their future performance. |
| 2026-03-17 17:48:48 Earnings are likely affected by stock price fluctuations and potential growth rate issues. |
| 2026-03-17 17:48:48 Concerns over stock performance due to projected growth rates falling short. |
| 2026-03-17 17:02:21 Despite recent downturns, some analysts suggest that Eli Lilly may present a 'buy the dip' opportunity for investors looking at long-term potential. |
| 2026-03-17 17:02:21 There are growing concerns regarding whether investors should reassess Eli Lilly's market valuation in light of the recent downgrades and stock performance. |
| 2026-03-17 17:02:21 Eli Lilly is facing stiff competition in the obesity drug market, primarily from rivals like Novo Nordisk, which raises questions about future sales growth. |
| 2026-03-17 17:02:21 Multiple analysts have issued downgrades for Eli Lilly, indicating concerns about inflated expectations for their obesity drugs and the overall stock valuation. |
| 2026-03-17 17:02:21 Eli Lilly's stock has experienced a notable decline, falling several percentage points following downgrades and adverse market conditions. |
| 2026-03-17 15:48:57 Eli Lilly’s stock has come under scrutiny after a strong previous period, leading to a downgrade and negative outlook from analysts. |
| 2026-03-17 15:48:57 The potential impact of economic downturns, like job losses and AI job displacement on consumer spending, is raised as a concern for sales of weight-loss drugs. |
| 2026-03-17 15:48:57 There are significant worries regarding increased price competition for Eli Lilly's products, particularly weight-loss drugs, which could impact sales. |
| 2026-03-17 15:48:57 The articles reflect a strong sentiment of concern among analysts regarding Eli Lilly's stock performance and future prospects. |
| 2026-03-17 13:49:02 Concerns about overestimated market growth for obesity drugs indicate potential issues in revenue projections and market excitement. |
| 2026-03-17 13:49:02 The expectation of pricing pressures on Eli Lilly's products suggests challenges in maintaining profit margins amidst competitive pressures. |
| 2026-03-17 13:49:02 Increasing competition in the obesity drug market poses significant challenges for Eli Lilly, impacting its sales and market position. |
| 2026-03-17 13:49:02 HSBC's downgrade of Eli Lilly due to concerns over pricing pressure and competition indicates negative sentiment regarding the company's future performance. |
| 2026-03-17 11:50:46 The downgrade of Eli Lilly's stock indicates concerns about its future performance following a strong run-up. |
| 2026-03-17 11:50:46 Eli Lilly faces significant competition in pricing, which poses challenges for its products Zepbound and Mounjaro. |
| 2026-03-17 09:35:25 Various stocks, including Eli Lilly, are noted for significant movements in the premarket, showing interest from investors. |
| 2026-03-17 09:35:25 The obesity drug market is experiencing volatility, with analysts anticipating a slowdown in growth. |